CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indivior Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indivior Pharmaceuticals Inc
10710 Midlothian Turnpike
Suite 125, North Chesterfield
Phone: (804) 379-1090p:804 379-1090 DOVER, VA  23235  United States
Business Summary
BRIEF: For the nine months ended 30 September 2025, Indivior Pharmaceuticals Inc revenues decreased 1% to $882M. Net income applicable to common stockholders totaled $106M vs. loss of $14M. Revenues reflect United States segment decrease of 2% to $745M. Net Income reflects Buprenorphine Based Drugs segment income increase from $75M to $181M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.10 to $0.85.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board David E.Wheadon 67 1/28/2025 6/1/2024
Chief Executive Officer, Director Joseph J.Ciaffoni 54 5/9/2025 12/17/2024
Chief Human Resources Officer AngelaColon-Mahoney 1/1/2024 1/1/2024
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Indivior Finance S.ar.l. Luxembourg
RBP Global Holdings, Ltd. 103-105 Bath Road Berkshire United Kingdom
Indivior plc United Kingdom
Opiant Pharmaceuticals Inc 233 Wilshire Blvd, Suite 400 SANTA MONICA CA United States
Indivior Finance (2014) LLC DE United States

Business Names
Business Name
A12FHW
Bio-Found Limited
Indivior (Beijing) Pharmaceuticals Information Consulting Co. Ltd
70 additional Business Names available in full report.

General Information
Number of Employees: 1,030 (As of 12/31/2024)
Outstanding Shares: 124,853,897 (As of 10/1/2025)
Shareholders: 1,027
Stock Exchange: LON
Federal Tax Id: 412520873


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026